Literature DB >> 9108400

Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women.

F R Rosendaal1, D S Siscovick, S M Schwartz, R K Beverly, B M Psaty, W T Longstreth, T E Raghunathan, T D Koepsell, P H Reitsma.   

Abstract

Factor V Leiden (factor V Arg506Gln), the genetic defect underlying resistance to activated protein C, is the most common risk factor for venous thrombosis. The relationship between this genetic abnormality and arterial disease is still unresolved. To assess whether factor V Leiden increases the risk of myocardial infarction (MI), we conducted a population-based case-control study among women 18 to 44 years of age in western Washington state. We included 84 women with first MI and 388 control women, ie, women residing in the same area in the same age range without MI (n = 388). The control women were contacted by random digit dialing. Data on risk factor status were collected via personal interview, and data on the factor V genotype via polymerase chain reaction techniques. The factor V Leiden mutation was found more often in women with MI (10%) than among controls (4%). The odds ratio for MI was 2.4 [95% confidence interval (CI) 1.0 to 5.9]. The risk was increased fourfold (CIgs 1.2 to 12.1) when adjusted for major cardiovascular risk factors. Among nonsmokers the factor V Leiden mutation had little effect (odds ratio 1.1, CI95 0.1 to 8.5), whereas it had a large effect among smokers (odds ratio 3.6, CI95 0.9 to 14.4), which, because smoking was itself a strong risk factor for MI, led to an odds ratio for smoking carriers of the mutation that was 32-fold increased compared with nonsmoking noncarriers. We conclude that factor V Leiden increases the risk of MI in young women. This effect seems to be confined largely to current smokers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108400

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

Review 1.  Diagnosis and management of inherited and acquired thrombophilias.

Authors:  F A Spencer; R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

3.  Spontaneous loss of early pregnancy and risk of ischaemic heart disease in later life: retrospective cohort study.

Authors:  Gordon C S Smith; Jill P Pell; David Walsh
Journal:  BMJ       Date:  2003-02-22

4.  Multiple thromboses at multiple sites. A known hereditary disease emerging late but suddenly and extensively.

Authors:  F Ozcan; N Sen; O Turak; S Okten; M F Ozlü
Journal:  Herz       Date:  2011-12-24       Impact factor: 1.443

5.  Incidence of factor V Leiden in patients with acute myocardial infarction.

Authors:  M S Gowda; M L Zucker; J L Vacek; W L Carriger; D L Van Laeys; J M Rachel; B D Strope
Journal:  J Thromb Thrombolysis       Date:  2000-01       Impact factor: 2.300

6.  Homozygous factor V Leiden mutation in type IV Ehlers-Danlos patient.

Authors:  Marwan Refaat; Mostafa Hotait; Brion Winston
Journal:  World J Clin Cases       Date:  2014-03-16       Impact factor: 1.337

Review 7.  Pediatric antiphospholipid syndrome.

Authors:  Cassyanne L Aguiar; Arzu Soybilgic; Tadej Avcin; Barry L Myones
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

8.  Prevalence of thrombotic risk factors among beta-thalassemia patients from Western Iran.

Authors:  Zohreh Rahimi; Mandana Ghaderi; Ronald L Nagel; Adriana Muniz
Journal:  J Thromb Thrombolysis       Date:  2007-11-04       Impact factor: 2.300

9.  Off-pump coronary artery bypass graft surgery after stent implantation in a patient with combined thrombophilic risk factors.

Authors:  Zeynep Eyileten; A Ruchan Akar; Mustafa Sirlak; Kemalettin Ucanok; Nejat Akar
Journal:  Can J Cardiol       Date:  2007-11       Impact factor: 5.223

10.  The prevalence of factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T among G6PD deficient individuals from Western Iran.

Authors:  Hadi Mozafari; Zohreh Rahimi; Azadeh Heidarpour; Mahsa Fallahi; Adraiana Muniz
Journal:  Mol Biol Rep       Date:  2009-02-15       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.